Categories

Conversations with IR officers, advisors, and public company executives on building an investor relations program that earns trust: messaging, investor targeting, shareholder engagement, and the evolving role of IR as a strategic advisor to the C-suite.

How companies prepare for and execute an IPO, from pre-IPO investor relations and the S-1 to roadshows, uplistings, and life as a newly public company.

Shareholder activism preparedness, board composition, and corporate governance: how public companies build defenses, engage shareholders, and protect long-term value.

Running effective roadshows, investor days, and investor meetings: preparing management, bringing back actionable intelligence, and presenting a story that holds up to scrutiny.

PIPE financing, Reg D offerings, and private placements: how issuers and sponsors structure and communicate private capital raises with institutional and accredited investors.

SEC disclosure, Reg FD, 13F filings, and the compliance realities every IR team and capital raiser has to navigate. Informational only, not legal advice.

How founders, fund managers, and public companies communicate with investors: earnings calls, transparency in good times and bad, LP updates, and the psychology behind every investor conversation.

Breaking into and growing a career in investor relations: credentials, career changes, hiring red flags, and what IR leaders say it takes to succeed.

How single and multi-family offices allocate capital, structure governance, and build lasting relationships with founders and fund managers, from CIO roles to multi-generational wealth.

How registered investment advisors evaluate private equity, private credit, and venture for client portfolios, and what fund managers and pre-IPO companies need to know to work with the RIA channel.

How VCs evaluate founders, what makes a startup fundable, pitch deck mistakes, and how venture funds build trust with their LPs.

Private equity, independent sponsors, private credit, and real estate funds: how GPs raise capital, structure fees, and communicate with LPs across the private markets.

The SPAC lifecycle from sponsor capital and trust to PIPEs, the S-4, redemptions, and de-SPAC investor relations, with the sponsors, investors, and advisors who work in the blank-check market.

Investor relations for biotech and life sciences companies across development stages: clinical trial communications, financing, turnarounds, and what boards and investors expect.

How founders, sponsors, and fund managers raise capital: investor targeting, outreach, pitch psychology, deal structure, and the relationships that close rounds.